{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:52Z","timestamp":1793933212261,"version":"4.8.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Verona Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s41030-025-00318-x","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:02:07Z","timestamp":1758945727000},"page":"553-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dyspnea in Chronic Obstructive Pulmonary Disease: Expert Assessment of Management in Clinical Practice"],"prefix":"10.1007","volume":"11","author":[{"given":"Nirupama","family":"Putcha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego J.","family":"Maselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-4610","authenticated-orcid":false,"given":"M. Bradley","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"318_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report. https:\/\/goldcopd.org\/2025-gold-report\/. Accessed 10 April 2025."},{"issue":"1","key":"318_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1164\/ajrccm.159.1.ats898","volume":"159","author":"American Thoracic Society","year":"1999","unstructured":"American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159(1):321\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"318_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-021-00329-9","volume":"11","author":"C Gutierrez Villegas","year":"2021","unstructured":"Gutierrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Paras-Bravo P, Madrazo Perez M. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. 2021;11(1):31.","journal-title":"Health Econ Rev"},{"issue":"1","key":"318_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0122-1","volume":"15","author":"M Miravitlles","year":"2014","unstructured":"Miravitlles M, Worth H, Soler Catalu\u00f1a JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15(1):122.","journal-title":"Respir Res"},{"issue":"4","key":"318_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/rccm.201111-2042ST","volume":"185","author":"MB Parshall","year":"2012","unstructured":"Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"318_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1378\/chest.09-2498","volume":"138","author":"M Williams","year":"2010","unstructured":"Williams M, Cafarella P, Olds T, Petkov J, Frith P. Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD. Chest. 2010;138(2):315\u201322.","journal-title":"Chest"},{"issue":"3","key":"318_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1378\/chest.08-1141","volume":"134","author":"DA Mahler","year":"2008","unstructured":"Mahler DA, Baird JC. Are you fluent in the language of dyspnea? Chest. 2008;134(3):476\u20137.","journal-title":"Chest"},{"issue":"12","key":"318_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1164\/rccm.202109-2171OC","volume":"205","author":"DB Phillips","year":"2022","unstructured":"Phillips DB, Elbehairy AF, James MD, et al. Impaired ventilatory efficiency, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease: results from the CanCOLD study. Am J Respir Crit Care Med. 2022;205(12):1391\u2013402.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"318_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ajhp\/zxz306","volume":"77","author":"SG Bollmeier","year":"2020","unstructured":"Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health-Syst Pharm. 2020;77(4):259\u201368.","journal-title":"Am J Health-Syst Pharm"},{"issue":"6","key":"318_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1183\/09031936.00031114","volume":"43","author":"RB Banzett","year":"2014","unstructured":"Banzett RB, O\u2019Donnell CR. Should we measure dyspnoea in everyone? Eur Respir J. 2014;43(6):1547\u201350.","journal-title":"Eur Respir J"},{"issue":"2","key":"318_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.23838\/pfm.2020.00212","volume":"5","author":"K-C Ong","year":"2021","unstructured":"Ong K-C. Evaluating dyspnoea in chronic obstructive pulmonary disease. Precis Future Med. 2021;5(2):62\u20138.","journal-title":"Precis Future Med"},{"issue":"3","key":"318_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/00325481.2017.1301190","volume":"129","author":"A Anzueto","year":"2017","unstructured":"Anzueto A, Miravitlles M. Pathophysiology of dyspnea in COPD. Postgrad Med. 2017;129(3):366\u201374.","journal-title":"Postgrad Med"},{"issue":"1","key":"318_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.resinv.2020.10.007","volume":"59","author":"I Fukushi","year":"2021","unstructured":"Fukushi I, Pokorski M, Okada Y. Mechanisms underlying the sensation of dyspnea. Respir Investig. 2021;59(1):66\u201380.","journal-title":"Respir Investig"},{"key":"318_CR14","unstructured":"Goldin J, Cascella M. Diffusing capacity of the lungs for carbon monoxide. Treasure Island (FL): StatPearls; 2025."},{"issue":"2","key":"318_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/0970-2113.80321","volume":"28","author":"NK Gupta","year":"2011","unstructured":"Gupta NK, Agrawal RK, Srivastav AB, Ved ML. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. Lung India. 2011;28(2):105\u20139.","journal-title":"Lung India"},{"issue":"1","key":"318_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085540","volume":"9","author":"H M\u00fcllerov\u00e1","year":"2014","unstructured":"M\u00fcllerov\u00e1 H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS ONE. 2014;9(1):e85540.","journal-title":"PLoS ONE"},{"issue":"1","key":"318_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12931-017-0548-3","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67.","journal-title":"Respir Res"},{"key":"318_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/COPD.S188141","volume":"14","author":"NA Hanania","year":"2019","unstructured":"Hanania NA, O\u2019Donnell DE. Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019;14:1127\u201338.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"318_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/arm91020011","volume":"91","author":"MS Rahi","year":"2023","unstructured":"Rahi MS, Thilagar B, Balaji S, et al. The impact of anxiety and depression in chronic obstructive pulmonary disease. Adv Respir Med. 2023;91(2):123\u201334.","journal-title":"Adv Respir Med"},{"issue":"1","key":"318_CR20","doi-asserted-by":"publisher","first-page":"2470566","DOI":"10.1080\/25310429.2025.2470566","volume":"31","author":"A M\u00fcller","year":"2025","unstructured":"M\u00fcller A, Wouters EFM, Burney P, et al. Quality of life associated with breathlessness in the multinational burden of obstructive lung disease (BOLD) study: a cross-sectional analysis. Pulmonology. 2025;31(1):2470566.","journal-title":"Pulmonology"},{"issue":"4","key":"318_CR21","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.4314\/ahs.v20i4.32","volume":"20","author":"EK Serin","year":"2020","unstructured":"Serin EK, Ister ED, Ozdemir A. The relationship between sleep quality and dyspnoea severity in patients with COPD. Afr Health Sci. 2020;20(4):1785\u201392.","journal-title":"Afr Health Sci"},{"key":"318_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.smrv.2016.02.007","volume":"32","author":"MS Shawon","year":"2017","unstructured":"Shawon MS, Perret JL, Senaratna CV, Lodge C, Hamilton GS, Dharmage SC. Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: a systematic review. Sleep Med Rev. 2017;32:58\u201368.","journal-title":"Sleep Med Rev"},{"issue":"2","key":"318_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.29328\/journal.jprr.1001060","volume":"8","author":"AP Daria","year":"2024","unstructured":"Daria AP, Tatiana VS, Ekaterina BB. Obesity in patients with chronic obstructive pulmonary disease as a separate clinical phenotype. J Pulmonol Respir Res. 2024;8(2):53\u20135.","journal-title":"J Pulmonol Respir Res"},{"issue":"1","key":"318_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1465-9921-8-18","volume":"8","author":"JP de Torres","year":"2007","unstructured":"de Torres JP, Casanova C, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respir Res. 2007;8(1):18.","journal-title":"Respir Res"},{"issue":"7","key":"318_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thx.54.7.581","volume":"54","author":"JC Bestall","year":"1999","unstructured":"Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581\u20136.","journal-title":"Thorax"},{"key":"318_CR26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2147\/COPD.S104947","volume":"11","author":"M Morishita-Katsu","year":"2016","unstructured":"Morishita-Katsu M, Nishimura K, Taniguchi H, et al. The COPD assessment test and St George\u2019s respiratory questionnaire: are they equivalent in subjects with COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:1543\u201351.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"318_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.pulmoe.2022.10.011","volume":"29","author":"R Meys","year":"2023","unstructured":"Meys R, Janssen SMJ, Franssen FME, et al. Test-retest reliability, construct validity and determinants of 6-minute walk test performance in adult patients with asthma. Pulmonology. 2023;29(6):486\u201394.","journal-title":"Pulmonology"},{"issue":"1","key":"318_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/COPD-200050666","volume":"2","author":"DA Mahler","year":"2005","unstructured":"Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99\u2013103.","journal-title":"COPD"},{"issue":"14","key":"318_CR29","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2169\/internalmedicine.49.3094","volume":"49","author":"ML Chuang","year":"2010","unstructured":"Chuang ML, Lee CH, Lin IF. Using the oxygen-cost diagram in ramp-slope selection for dyspneic patients. Intern Med. 2010;49(14):1325\u201332.","journal-title":"Intern Med"},{"issue":"9","key":"318_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1249\/00005768-199409000-00002","volume":"26","author":"DA Mahler","year":"1994","unstructured":"Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc. 1994;26(9):1078\u201381.","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"318_CR31","doi-asserted-by":"publisher","first-page":"2416815","DOI":"10.1016\/j.pulmoe.2024.03.005","volume":"31","author":"A M\u00fcller","year":"2024","unstructured":"M\u00fcller A, Wouters EF, Koul P, et al. Association between lung function and dyspnoea and its variation in the multinational burden of obstructive lung disease (BOLD) study. Pulmonology.\u00a02025;31(1):2416815.","journal-title":"Pulmonology"},{"key":"318_CR32","first-page":"187","volume":"9","author":"P Gagnon","year":"2014","unstructured":"Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:187\u2013201.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"318_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/bja\/aer040","volume":"106","author":"T Nishino","year":"2011","unstructured":"Nishino T. Dyspnoea: underlying mechanisms and treatment. Br J Anaesth. 2011;106(4):463\u201374.","journal-title":"Br J Anaesth"},{"issue":"2","key":"318_CR34","first-page":"210","volume":"84","author":"JA Wedzicha","year":"2000","unstructured":"Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(2):210\u20135.","journal-title":"Thromb Haemost"},{"issue":"6","key":"318_CR35","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.chest.2021.01.004","volume":"159","author":"KA Serban","year":"2021","unstructured":"Serban KA, Pratte KA, Bowler RP. Protein biomarkers for COPD outcomes. Chest. 2021;159(6):2244\u201353.","journal-title":"Chest"},{"issue":"1","key":"318_CR36","doi-asserted-by":"publisher","first-page":"00301-2022","DOI":"10.1183\/23120541.00301-2022","volume":"9","author":"L Vanfleteren","year":"2023","unstructured":"Vanfleteren L, Weidner J, Franssen FME, et al. Biomarker-based clustering of patients with chronic obstructive pulmonary disease. ERJ Open Res.\u00a02023;9(1):00301-2022.","journal-title":"ERJ Open Res"},{"issue":"4","key":"318_CR37","first-page":"430","volume":"5","author":"EE Akpinar","year":"2013","unstructured":"Akpinar EE, Ho\u015fg\u00fcn D, Do\u011fanay B, Ata\u00e7 GK, G\u00fclhan M. Should the cut-off value of D-dimer be elevated to exclude pulmonary embolism in acute exacerbation of COPD? J Thorac Dis. 2013;5(4):430\u20134.","journal-title":"J Thorac Dis"},{"issue":"1","key":"318_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amjmed.2015.06.037","volume":"129","author":"GA Alba","year":"2016","unstructured":"Alba GA, Truong QA, Gaggin HK, et al. Diagnostic and prognostic utility of procalcitonin in patients presenting to the emergency department with dyspnea. Am J Med. 2016;129(1):96-104.e7.","journal-title":"Am J Med"},{"key":"318_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.901990","volume":"9","author":"D Mu","year":"2022","unstructured":"Mu D, Cheng J, Qiu L, Cheng X. Copeptin as a diagnostic and prognostic biomarker in cardiovascular diseases. Front Cardiovasc Med. 2022;9:901990.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"318_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12890-016-0345-7","volume":"17","author":"NM Hawkins","year":"2017","unstructured":"Hawkins NM, Khosla A, Virani SA, McMurray JJ, FitzGerald JM. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med. 2017;17(1):11.","journal-title":"BMC Pulm Med"},{"key":"318_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/COPD.S396663","volume":"18","author":"X Su","year":"2023","unstructured":"Su X, Lei T, Yu H, et al. NT-proBNP in different patient groups of COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:811\u201325.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"49","key":"318_CR42","first-page":"834","volume":"113","author":"D Berliner","year":"2016","unstructured":"Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of dyspnea. Dtsch Arztebl Int. 2016;113(49):834\u201345.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"318_CR43","first-page":"Cd000238","volume":"2014","author":"F Ameer","year":"2014","unstructured":"Ameer F, Carson KV, Usmani ZA, Smith BJ. Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest. Cochrane Database Syst Rev. 2014;2014(6):Cd000238.","journal-title":"Cochrane Database Syst Rev"},{"key":"318_CR44","unstructured":"Ohtuvayre. Ensifentrine [Internet]. 2024. https:\/\/ohtuvayrehcp.com\/wp-content\/uploads\/sites\/2\/2024\/11\/Ohtuvayre-US-Prescribing-Information.pdf. Accessed 12 June 2025."},{"issue":"9","key":"318_CR45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17512433.2020.1817739","volume":"13","author":"P Rogliani","year":"2020","unstructured":"Rogliani P, Ritondo BL, Gabriele M, Cazzola M, Calzetta L. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020;13(9):977\u201390.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"318_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/14799731251314874","volume":"22","author":"M Dransfield","year":"2025","unstructured":"Dransfield M, Marchetti N, Kalhan R, et al. Ensifentrine in COPD patients taking long-acting bronchodilators: a pooled post-hoc analysis of the ENHANCE-1\/2 studies. Chron Respir Dis. 2025;22:14799731251314874.","journal-title":"Chron Respir Dis"},{"issue":"4","key":"318_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","volume":"208","author":"A Anzueto","year":"2023","unstructured":"Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase\u00a0III trials (the ENHANCE trials). Am J Respir Crit Care Med. 2023;208(4):406\u201316.","journal-title":"Am J Respir Crit Care Med"},{"key":"318_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/14799731231166008","volume":"20","author":"K Tanimura","year":"2023","unstructured":"Tanimura K, Sato S, Fujita Y, et al. The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Chron Respir Dis. 2023;20:14799731231166008.","journal-title":"Chron Respir Dis"},{"key":"318_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4137\/CCRPM.S7211","volume":"7","author":"S Ejiofor","year":"2013","unstructured":"Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17\u201334.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"3","key":"318_CR50","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.jpainsymman.2022.11.018","volume":"65","author":"ST Simon","year":"2023","unstructured":"Simon ST, Mori M, Ekstr\u00f6m M, Pralong A, Yamaguchi T, Hui D. Should benzodiazepines be used for reducing dyspnea in patients with advanced illnesses? J Pain Symptom Manage. 2023;65(3):e219\u201323.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"318_CR51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/jpm14030318","volume":"14","author":"R-M Rajnoveanu","year":"2024","unstructured":"Rajnoveanu R-M, Harangus A, Todea DA, Man MA, Budin CE, Rajnoveanu A-G. Opioids in treatment of refractory dyspnea in chronic obstructive pulmonary disease: yes, no or maybe. J Pers Med. 2024;14(3):318.","journal-title":"J Pers Med"},{"key":"318_CR52","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2147\/COPD.S467131","volume":"19","author":"H Jiang","year":"2024","unstructured":"Jiang H, Zhang X, Zhang J, Liang J, Wang L. Association between opioid and benzodiazepine use and all-cause mortality in individuals with chronic obstructive pulmonary disease: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2024;19:2181\u201392.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"318_CR53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12890-023-02566-6","volume":"23","author":"J Kocks","year":"2023","unstructured":"Kocks J, Bosnic-Anticevich S, van Cooten J, et al. Identifying critical inhalation technique errors in dry powder inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med. 2023;23(1):302.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"318_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14073","volume":"75","author":"HS Harb","year":"2021","unstructured":"Harb HS, Ibrahim Laz N, Rabea H, Abdelrahim MEA. Determinants of incorrect inhaler technique in chronic obstructive pulmonary disease patients. Int J Clin Pract. 2021;75(6):e14073.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"318_CR55","first-page":"2355","volume":"11","author":"S Bosnic-Anticevich","year":"2023","unstructured":"Bosnic-Anticevich S, Bender BG, Shuler MT, Hess M, Kocks JWH. Recognizing and tackling inhaler technique decay in asthma and chronic obstructive pulmonary disesase (COPD) clinical practice. J Allergy Clin Immunol: In Pract. 2023;11(8):2355-64.e5.","journal-title":"J Allergy Clin Immunol: In Pract"},{"issue":"2","key":"318_CR56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s41030-020-00133-6","volume":"6","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, van Boven JFM. Switching inhalers: a practical approach to keep on UR RADAR. Pulm Ther. 2020;6(2):381\u201392.","journal-title":"Pulm Ther"},{"key":"318_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106583","volume":"187","author":"TG Capstick","year":"2021","unstructured":"Capstick TG, Azeez NF, Deakin G, Goddard A, Goddard D, Clifton IJ. Ward based inhaler technique service reduces exacerbations of asthma and COPD. Respir Med. 2021;187:106583.","journal-title":"Respir Med"},{"issue":"1","key":"318_CR58","first-page":"37","volume":"11","author":"KI Duan","year":"2024","unstructured":"Duan KI, Donovan LM, Spece LJ, et al. Inhaler formulary change in COPD and the association with exacerbations, health care utilization, and costs. Chronic Obstr Pulm Dis. 2024;11(1):37\u201346.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"163","key":"318_CR59","doi-asserted-by":"publisher","first-page":"210215","DOI":"10.1183\/16000617.0215-2021","volume":"31","author":"R Hanewinkel","year":"2022","unstructured":"Hanewinkel R, Niederberger K, Pedersen A, Unger JB, Galimov A. E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials. Eur Respir Rev.\u00a02022;31(163):210215.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"318_CR60","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/ntr\/ntaf067","volume":"27","author":"J Erhabor","year":"2025","unstructured":"Erhabor J, Yao Z, Tasdighi E, Benjamin EJ, Bhatnagar A, Blaha MJ. E-cigarette use and incident cardiometabolic conditions in the All of Us research program. Nicotine Tob Res. 2025;27(9):1651\u20131656.","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"318_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01884-5","volume":"22","author":"J Hagenburg","year":"2022","unstructured":"Hagenburg J, Bertin E, Salmon JH, et al. Association between obesity-related dyspnea in daily living, lung function and body composition analyzed by DXA: a prospective study of 130 patients. BMC Pulm Med. 2022;22(1):103.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"318_CR62","doi-asserted-by":"publisher","first-page":"00094-2018","DOI":"10.1183\/23120541.00094-2018","volume":"4","author":"K Heslop-Marshall","year":"2018","unstructured":"Heslop-Marshall K, Baker C, Carrick-Sen D, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res.\u00a02018;4(4):00094-2018.","journal-title":"ERJ Open Res"},{"key":"318_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2023.104070","volume":"313","author":"C Koga","year":"2023","unstructured":"Koga C, Mase K, Takashima S, Yamamoto K, Mineoka R, Ozaki K. Work of breathing and lung volume during forward leaning supported by the upper limbs. Respir Physiol Neurobiol. 2023;313:104070.","journal-title":"Respir Physiol Neurobiol"},{"issue":"4","key":"318_CR64","first-page":"444","volume":"10","author":"MV Benzo","year":"2023","unstructured":"Benzo MV, Barwise A, Clark MM, Dupuy-McCauley K, Roy M, Benzo RP. Improving dyspnea by targeting weight loss in patients with chronic obstructive lung disease and severe obesity through health coaching and remote monitoring. Chronic Obstr Pulm Dis. 2023;10(4):444\u20139.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"7","key":"318_CR65","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/nu15071786","volume":"15","author":"A Tramontano","year":"2023","unstructured":"Tramontano A, Palange P. Nutritional state and COPD: effects on dyspnoea and exercise tolerance. Nutrients.\u00a02023;15(7):1786.","journal-title":"Nutrients"},{"issue":"4","key":"318_CR66","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1097\/HNP.0000000000000531","volume":"36","author":"A Ne\u015fe","year":"2022","unstructured":"Ne\u015fe A, Samanc\u0131o\u011flu Ba\u011flama S. The effect of progressive muscle relaxation and deep breathing exercises on dyspnea and fatigue symptoms of COPD patients: a randomized controlled study. Holist Nurs Pract. 2022;36(4):E18-e26.","journal-title":"Holist Nurs Pract"},{"issue":"1","key":"318_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000367635","volume":"84","author":"I Farver-Vestergaard","year":"2015","unstructured":"Farver-Vestergaard I, Jacobsen D, Zachariae R. Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Psychother Psychosom. 2015;84(1):37\u201350.","journal-title":"Psychother Psychosom"},{"issue":"4","key":"318_CR68","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3109\/15412555.2010.496820","volume":"7","author":"J Spahija","year":"2010","unstructured":"Spahija J, Marchie M, Ghezzo H, Grassino A. Factors discriminating spontaneous pursed-lips breathing use in patients with COPD. COPD. 2010;7(4):254\u201361.","journal-title":"COPD"},{"issue":"5","key":"318_CR69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.2019.22343","volume":"323","author":"ME Wilson","year":"2020","unstructured":"Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2020;323(5):455\u201365.","journal-title":"JAMA"},{"key":"318_CR70","unstructured":"Mobility aids: a comprehensive guide for COPD patients: LPT medical; 2025. https:\/\/lptmedical.com\/blogs\/respiratory-resource-center\/mobility-aids-a-comprehensive-guide-for-copd-patients?srsltid=AfmBOoqj5GoK_oXzftjeqWwSb3nBOLMEAxXUlz9504em4s-QlLmT27Vs. Accessed 9 June 2025."},{"issue":"7","key":"318_CR71","doi-asserted-by":"publisher","first-page":"998","DOI":"10.4187\/respcare.10876","volume":"68","author":"MW Hess","year":"2023","unstructured":"Hess MW. Oxygen therapy in COPD. Respir Care. 2023;68(7):998\u20131012.","journal-title":"Respir Care"},{"issue":"7","key":"318_CR72","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.mayocp.2017.03.020","volume":"92","author":"S Mirza","year":"2017","unstructured":"Mirza S, Benzo R. Chronic obstructive pulmonary disease phenotypes: implications for care. Mayo Clin Proc. 2017;92(7):1104\u201312.","journal-title":"Mayo Clin Proc"},{"key":"318_CR73","doi-asserted-by":"publisher","first-page":"100117","DOI":"10.1016\/j.chpulm.2024.100117","volume":"3","author":"DJ Franco-Palacios","year":"2024","unstructured":"Franco-Palacios DJ, Priebe R, Simanovski J, et al. Bronchoscopic lung volume reduction: effect on symptoms and lung function in patients with emphysema that qualify for lung transplant. CHEST Pulm. 2024;3:100117.","journal-title":"CHEST Pulm"},{"key":"318_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106825","volume":"196","author":"JE Hartman","year":"2022","unstructured":"Hartman JE, Welling JBA, Klooster K, Carpaij OA, Augustijn SWS, Slebos DJ. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respir Med. 2022;196:106825.","journal-title":"Respir Med"},{"issue":"1","key":"318_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01664-5","volume":"22","author":"C Pison","year":"2021","unstructured":"Pison C, Shah PL, Slebos D-J, et al. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. Respir Res. 2021;22(1):62.","journal-title":"Respir Res"},{"issue":"2","key":"318_CR76","first-page":"69","volume":"18","author":"DD Marciniuk","year":"2011","unstructured":"Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69\u201378.","journal-title":"Can Respir J"},{"issue":"3","key":"318_CR77","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1378\/chest.121.3.688","volume":"121","author":"SD Aaron","year":"2002","unstructured":"Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest. 2002;121(3):688\u201396.","journal-title":"Chest"},{"issue":"Suppl B","key":"318_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","volume":"85","author":"PW Jones","year":"1991","unstructured":"Jones PW, Quirk FH, Baveystock CM. The St George\u2019s respiratory questionnaire. Respir Med. 1991;85(Suppl B):25\u201331.","journal-title":"Respir Med"},{"issue":"6","key":"318_CR79","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s respiratory questionnaire. Am Rev Respir Dis. 1992;145(6):1321\u20137.","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"318_CR80","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/thx.42.10.773","volume":"42","author":"GH Guyatt","year":"1987","unstructured":"Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773\u20138.","journal-title":"Thorax"},{"issue":"3","key":"318_CR81","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648\u201354.","journal-title":"Eur Respir J"},{"key":"318_CR82","unstructured":"The Evaluating Respiratory Symptoms (E-RS): COPD scale is used to measure the effect of treatment on the severity of respiratory symptoms in stable chronic obstructive pulmonary disease (COPD): PPD; 2025. https:\/\/www.ppd.com\/our-solutions\/clinical\/real-world-evidence\/patient-centered-research-studies\/coa-instrument-management-services\/the-ers-copd\/. Accessed 10 April 2025."},{"issue":"2","key":"318_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2340\/1650197719702239298","volume":"2","author":"G Borg","year":"1970","unstructured":"Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92\u20138.","journal-title":"Scand J Rehabil Med"},{"issue":"6","key":"318_CR84","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751\u20138.","journal-title":"Chest"},{"issue":"3","key":"318_CR85","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","volume":"93","author":"DA Mahler","year":"1988","unstructured":"Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580\u20136.","journal-title":"Chest"},{"issue":"2","key":"318_CR86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/COPD-120030829","volume":"1","author":"DA Mahler","year":"2004","unstructured":"Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1(2):165\u201372.","journal-title":"COPD"},{"issue":"6132","key":"318_CR87","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bmj.2.6132.241","volume":"2","author":"CR McGavin","year":"1978","unstructured":"McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978;2(6132):241\u20133.","journal-title":"Br Med J"},{"issue":"1","key":"318_CR88","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"318_CR89","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/thx.47.12.1019","volume":"47","author":"SJ Singh","year":"1992","unstructured":"Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992;47(12):1019\u201324.","journal-title":"Thorax"},{"issue":"3","key":"318_CR90","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/thx.54.3.213","volume":"54","author":"SM Revill","year":"1999","unstructured":"Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax. 1999;54(3):213\u201322.","journal-title":"Thorax"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00318-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:13Z","timestamp":1763424253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00318-x","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nirupama Putcha has served on advisory boards for Verona Pharma and AstraZeneca. Diego J. Maselli has served on consulting\/advisory boards for GSK, AstraZeneca, Amgen, Sanofi\/Regeneron, Insmed, and Verona Pharma; and has received speaker fees from GSK, AstraZeneca, Amgen, and Sanofi\/Regeneron. Jessica Bon has received grant funding from the National Heart, Lung, and Blood Institute (NHLBI); has served on consulting\/advisory boards for GSK, Sanofi\/Regeneron, Verona Pharma, and Chiesi; and has received speaker fees from GSK and Sanofi\/Regeneron. Michael G. Lester has served on consulting\/advisory boards for Ryme Medical, Galvanize Therapeutics, and Verona Pharma. M. Bradley Drummond has served on consulting\/advisory boards for GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Verona, Genentech, Stratos Inc, Takeda, and Amgen and has received grant funding from National Institute of Health-NHLBI, Boehringer Ingelheim, Midmark, Teva and the American Lung Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Given that this article is based on previously conducted studies and does not report any new research involving human participants or animals performed by any of the authors, there is no ethical compliance to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}